Biogen Inc. $BIIB Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in Biogen Inc. (NASDAQ:BIIB) by 8.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,255,168 shares of the biotechnology company’s stock after selling 122,400 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.85% of Biogen worth $271,192,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in BIIB. BlackRock Inc. acquired a new stake in shares of Biogen in the 2nd quarter worth approximately $3,453,878,000. Primecap Management Co. CA acquired a new position in Biogen during the second quarter worth $3,274,304,000. Geode Capital Management LLC boosted its position in Biogen by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after purchasing an additional 130,618 shares in the last quarter. Wellington Management Group LLP boosted its position in Biogen by 5.3% during the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after purchasing an additional 155,828 shares in the last quarter. Finally, Norges Bank acquired a new stake in Biogen in the fourth quarter valued at $464,408,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Down 0.8%

BIIB opened at $216.65 on Tuesday. The firm has a market cap of $32.01 billion, a P/E ratio of 38.35, a PEG ratio of 6.81 and a beta of 0.17. The business’s fifty day simple moving average is $208.15 and its 200 day simple moving average is $195.89. Biogen Inc. has a 52 week low of $131.52 and a 52 week high of $222.85. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on BIIB shares. Mizuho raised their price target on Biogen from $221.00 to $241.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. UBS Group boosted their price objective on shares of Biogen from $225.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Piper Sandler restated an “overweight” rating on shares of Biogen in a report on Tuesday, July 14th. HSBC restated a “reduce” rating and set a $157.00 target price on shares of Biogen in a research report on Monday, July 6th. Finally, Zacks Research upgraded shares of Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and an average price target of $227.79.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.